0.05Open0.05Pre Close0 Volume180 Open Interest10.00Strike Price0.00Turnover465.71%IV633.58%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1030Delta0.1195Gamma27.40Leverage Ratio-0.0065Theta0.0001Rho2.82Eff Leverage0.0006Vega
Tempest Therapeutics Stock Discussion
Tempest Therapeutics, a clinical-stage biotechnology firm, recently announced a major milestone in their development of amezalpat (TPST-1120), a promising therapeutic agent for treating first-line unresec...
another good rating for a price target.
I wouldn't complain about 13.00 dollars
I want some of that 47 dollars share price target....lfg
No comment yet